Portal de Periódicos da CAPES

Novel Systemic Therapies in Advanced Liposarcoma: A Review of Recent Clinical Trial Results

2013; Multidisciplinary Digital Publishing Institute; Volume: 5; Issue: 2 Linguagem: Inglês

10.3390/cancers5020529

2072-6694

William W. Tseng, Neeta Somaiah, Alexander J. Lazar, Dina Lev, Raphael E. Pollock,

Protein Degradation and Inhibitors

Liposarcoma is one of the most common adult soft tissue sarcomas and consists of three histologic subtypes (well and dedifferentiated, myxoid/round cell, and pleomorphic). Surgery is the mainstay of treatment for localized disease; however for unresectable or metastatic disease, effective treatment options are currently limited. In the past decade, a better understanding of the distinct genetic and molecular aberrations for each of the three histologic subtypes has led to the development of several novel systemic therapies. Data from phase I and early phase II clinical trials have been reported. Despite challenges with conducting clinical trials in liposarcoma, preliminary results for several of these novel, biology-driven therapies are encouraging.